Multivessel angioplasty in acute myocardial infarction improves prognosis

Original title: Acute multivessel revascularization improves 1 year outcomes in ST-elevation myocardial infarction. A nationwide study from AMIS plus registry. Reference: Raban Jeger, et al. International journal of Cardiology 2014;172:76-81   The presence of multiple vessel lesions is present in about 50% of patients referred for primary angioplasty. The accepted strategy is to treat the culprit artery even<a href="https://solaci.org/en/2014/03/07/multivessel-angioplasty-in-acute-myocardial-infarction-improves-prognosis/" title="Read more" >...</a>

Best results of angioplasty with DES guided by IVUS versus angiography only

Original title: Intravascular Ultrasound-Guided Implantation of Drug-Eluting Stents to Improve Outcome. A Meta-Analysis. Reference: Jae-Sik Jang et al. J Am Coll Cardiol Intv 2014, epub ahead of print. Several previous studies and meta-analysis showed that implantation of conventional stents (BMS) intravascular ultrasound (IVUS) guided may decrease restenosis and clinical events. This information was not yet clear to drug-eluting<a href="https://solaci.org/en/2014/02/26/best-results-of-angioplasty-with-des-guided-by-ivus-versus-angiography-only/" title="Read more" >...</a>

The length of the stent is not an event predictor with the new generation of DES. It is the end of the Spot stenting?

Original title: Impact of the Stent Length on Long-Term Clinical Outcomes Following Newer-Generation Drug-Eluting Stent Implantation. Reference: Ik Jun Choi et al. Am J Cardiol 2014;113:457-464. Completely cover the lesion with a sufficiently long stent has been the preferred strategy that emerged from drug-eluting stents (DES). However, for the first-generation DES stent length has been a predictor of<a href="https://solaci.org/en/2014/02/20/the-length-of-the-stent-is-not-an-event-predictor-with-the-new-generation-of-des-it-is-the-end-of-the-spot-stenting/" title="Read more" >...</a>

Hybrid revascularization versus conventional surgery. Advantages and disadvantages for choosing ideal patients.

Original title: Clinical Outcomes after Hybrid Coronary Revascularization versus Coronary Artery Bypass Surgery: A Meta-Analysis of 1,190 Patients. Reference: Ralf E. Harskamp et al. American Heart Journal (2014), epub ahead of print.   Hybrid revascularization combines long-term patency of the mammary artery connected to the left anterior descending with minimally invasive drug-eluting stents to other injuries. This in<a href="https://solaci.org/en/2014/02/18/hybrid-revascularization-versus-conventional-surgery-advantages-and-disadvantages-for-choosing-ideal-patients/" title="Read more" >...</a>

3rd generation zotarolimus-eluting stent non- inferior to everolimus

Original title: Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomized, single-blind, multicentre, non-inferiority trial. Reference: Von Birgelen C et al. The Lancet. 2014; Epub ahead of print. In the 3rd generation zotarolimus-eluting stent, platform was modified to increase flexibility and make implant easier in complex lesions. This study was<a href="https://solaci.org/en/2014/02/13/3rd-generation-zotarolimus-eluting-stent-non-inferior-to-everolimus/" title="Read more" >...</a>

Decreased bleeding with radial access leaves little to bivalirudin for additional benefit

Original title: Bivalirudin or heparin in primary angioplasty performed through the transradial approach: results from a multicentre registry. Reference: Sciahbasi A et al. Eur Heart J: Acute Cardiovasc Care. Epub ahead of print. Bivalirudin benefit has been demonstrated in terms of bleeding; however when primary angioplasty is performed by radial access this information is not clear. To get<a href="https://solaci.org/en/2014/01/31/decreased-bleeding-with-radial-access-leaves-little-to-bivalirudin-for-additional-benefit/" title="Read more" >...</a>

Everolimus-eluting stent and DEB in restenosis for BMS. Good results of both with some expected differences.

Original title: A Randomized Comparison of Drug-Eluting Balloon Versus Everolimus-Eluting Stent in Patients With Bare-Metal Stent In-Stent Restenosis: The RIBS V Clinical Trial. Reference: Fernando Alfonso et al. J Am Coll Cardiol. 2014; Epub ahead of print.   Drug-eluting stents (DES) have proven to be superior in terms of restenosis than bare metal stents (BMS). BMS, however due<a href="https://solaci.org/en/2014/01/22/everolimus-eluting-stent-and-deb-in-restenosis-for-bms-good-results-of-both-with-some-expected-differences/" title="Read more" >...</a>

Longer follow-up registry of angioplasty in left main coronary artery. Significant differences according to the diseased segment.

Original title: The DELTA Registry (Drug-Eluting Stent for Left Main Coronary Artery Disease): A Multicenter registry Evaluating Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for left Main Treatment Reference: Naganuma T, et al. J Am Coll Cardiol Intv 2013;6:1242–9 Angioplasty of the unprotected left coronary trunk has increased significantly in recent years showing good results. Currently the<a href="https://solaci.org/en/2014/01/20/longer-follow-up-registry-of-angioplasty-in-left-main-coronary-artery-significant-differences-according-to-the-diseased-segment/" title="Read more" >...</a>

Unprotected trunk in diabetics: angioplasty with good long-term results but more revascularization

Original title: Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: D-DELTA registry. Reference: Meliga Emanuele, et al. EuroIntervention 2013; 9:803-808 Diabetes increases cardiovascular risk events because of their involvement in diffuse form of the vessels, thereby generating more events and changes in revascularization strategy<a href="https://solaci.org/en/2013/12/12/unprotected-trunk-in-diabetics-angioplasty-with-good-long-term-results-but-more-revascularization/" title="Read more" >...</a>

Everolimus -eluting stent to 3 years, most security was the key difference.

Original title: Everolimus-eluting stents in patients undergoing percutaneous coronary Intervention: Final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. Reference: Sorin J. Brener et al. Am Heart J 2013;0:1-8. The XIENCE stent (Abbott Vascular, Santa Clara, CA) is<a href="https://solaci.org/en/2013/12/10/everolimus-eluting-stent-to-3-years-most-security-was-the-key-difference/" title="Read more" >...</a>